BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BGB-21447 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BGB-21447\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06756932-9109@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:BGB-21447: Phase 1 readout est. (NCT06756932)
DESCRIPTION:BGB-21447\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Recept
 or Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-
 ) Metastatic Breast Cancer\nEstimated primary completion: 30 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bgb-21447#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06756932
URL:https://assetmemo.bio/drug/bgb-21447#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
